Selumitinib (AZD6244; ARRY-142886), a recent generation non-ATP competitive inhibitor of Mek1/2, displayed preclinical anti-tumorigenic effects in colorectal carcinoma, non-small cell lung cancer (NSCLC) melanoma and BC [11, 23, 24]. The gene discussed is MAP2K1; the disease is colorectal carcinoma.